Safety and Efficacy of the Ultimaster Stent

Launched by YONSEI UNIVERSITY · Dec 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a new type of heart stent called the Ultimaster stent, which is designed to treat coronary artery disease. Coronary artery disease happens when the blood vessels supplying the heart become narrowed or blocked, leading to symptoms like chest pain or even heart attacks. The Ultimaster stent is made with a special material that breaks down in the body over a few months, which may help reduce the risk of complications compared to traditional stents.

To participate in this trial, you need to be at least 19 years old and have a diagnosis of coronary artery disease. This includes different conditions like stable chest pain or recent heart issues. Participants must also agree to take part in the study by signing a consent form. If you think you might be interested in this trial, keep in mind that it is currently active but not recruiting new participants. This means that while the study is ongoing, they are not looking for new patients to join at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 19 or older
• • 2. Clinical evidence of coronary artery disease, including asymptomatic ischemia, stable angina, and acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction)
• • 3. No restrictions on the number of blood vessels, number of lesions, and length of lesions
• • 4. Those who voluntarily gave written consent to participate in this clinical study
• Exclusion Criteria:
• • 1. Life expectancy within 1 year
• • 2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, prasugrel, ticagrelor
• • 3. If other researchers judge that it is inappropriate to participate in this study